A PHASE II COMPARATIVE STUDY OF GROSS TUMOR VOLUME DEFINITION WITH OR WITHOUT PET/CT FUSION IN DOSIMETRIC PLANNING FOR NON-SMALL-CELL LUNG CANCER (NSCLC): PRIMARY ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP (RTOG) 0515

被引:68
作者
Bradley, Jeffrey [1 ]
Bae, Kyounghwa [2 ]
Choi, Noah [3 ]
Forster, Ken [4 ]
Siegel, Barry A.
Brunetti, Jacqueline [5 ]
Purdy, James [6 ]
Faria, Sergio [7 ]
Vu, Toni [8 ]
Thorstad, Wade
Choy, Hak [9 ]
机构
[1] Washington Univ, Sch Med, Dept Radiat Oncol, Alvin J Siteman Comprehens Canc Ctr, Washington, DC USA
[2] RTOG, Dept Stat, Philadelphia, PA USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[5] Holy Name Med Ctr, Teaneck, NJ USA
[6] Univ Calif Davis, Davis, CA 95616 USA
[7] McGill Univ, Montreal, PQ, Canada
[8] Univ Montreal, Notre Dame Hosp, Ctr Hosp Univ Montreal, Montreal, PQ H3C 3J7, Canada
[9] Univ Texas SW, Dallas, TX USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 82卷 / 01期
关键词
Lung cancer; FDG-PET; Mediastinal nodal staging; mediastinum;
D O I
10.1016/j.ijrobp.2010.09.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Radiation Therapy Oncology Group (RTOG) 0515 is a Phase II prospective trial designed to quantify the impact of positron emission tomography (PET)/computed tomography (CT) compared with CT alone on radiation treatment plans (RTPs) and to determine the rate of elective nodal failure for PET/CT-derived volumes. Methods: Each enrolled patient underwent definitive radiation therapy for non small-cell lung cancer (>= 60 Gy) and had two RTP datasets generated: gross tumor volume (GTV) derived with CTalone and with PET/CT. Patients received treatment using the PET/CT-derived plan. The primary end point, the impact of PET/CT fusion on treatment plans was measured by differences of the following variables for each patient: GTV, number of involved nodes, nodal station, mean lung dose (MLD), volume of lung exceeding 20 Gy (V20), and mean esophageal dose (MED). Regional failure rate was a secondary end point. The nonparametric Wilcoxon matched-pairs signed-ranks test was used with Bonferroni adjustment for an overall significance level of 0.05. Results: RTOG 0515 accrued 52 patients, 47 of whom are evaluable. The follow-up time for all patients is 12.9 months (2.7-22.2). Tumor staging was as follows: 11 = 6%; IIIA = 40%; and IIIB = 54%. The GTV was statistically significantly smaller for PET/CT-derived volumes (98.7 vs. 86.2 mL; p < 0.0001). MLDs for PET/CT plans were slightly lower (19 vs. 17.8 Gy; p = 0.06). There was no significant difference in the number of involved nodes (2.1 vs. 2.4), V20 (32% vs. 30.8%), or MED (28.7 vs. 27.1 Gy). Nodal contours were altered by PET/CT for 51% of patients. One patient (2%) has developed an elective nodal failure. Conclusions: PET/CT-derived tumor volumes were smaller than those derived by CT alone. PET/CT changed nodal GTV contours in 51% of patients. The elective nodal failure rate for GTVs derived by PET/CT is quite low, supporting the RTOG standard of limiting the target volume to the primary tumor and involved nodes. (C) 2012 Elsevier Inc.
引用
收藏
页码:435 / 441
页数:7
相关论文
共 6 条
[1]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[2]  
Greene F., 2002, AJCC cancer staging handbook: From the AJCC cancer staging manual, V6th
[3]   Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006-2007 [J].
MacManus, Michael ;
Nestle, Ursula ;
Rosenzweig, Kenneth E. ;
Carrio, Ignasi ;
Messa, Cristina ;
Belohlavek, Otakar ;
Danna, Massimo ;
Inoue, Tomio ;
Deniaud-Alexandre, Elizabeth ;
Schipani, Stefano ;
Watanabe, Naoyuki ;
Dondi, Maurizio ;
Jeremic, Branislav .
RADIOTHERAPY AND ONCOLOGY, 2009, 91 (01) :85-94
[4]   The effect of FDG-PET on the stage distribution of non-small cell lung cancer [J].
Morgensztern, Daniel ;
Goodgame, Boone ;
Baggstrom, Maria Q. ;
Govindan, Ramaswamy ;
Gao, Feng .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) :135-139
[5]   Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC):: The technical basis, ICRU-target volumes, problems, perspectives [J].
Nestle, Ursula ;
Kremp, Stephanie ;
Grosu, Anca-Ligia .
RADIOTHERAPY AND ONCOLOGY, 2006, 81 (02) :209-225
[6]   Noninvasive staging of non-small cell lung cancer - A review of the current evidence [J].
Toloza, EM ;
Harpole, L ;
McCrory, DC .
CHEST, 2003, 123 (01) :137S-146S